• Latest
  • Sectors
    • Pharma
    • Biotech
    • MedTech
    • Regulation & Industry
  • In-House
  • Careers
  • Events
    • Events
    • Events News
    • Events Videos
    • Webinars
  • Insights
    • Whitepapers
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate
18 March 2021

Trends at the Patent Trial and Appeal Board of the US Patent and Trademark Office: Is the Pendulum Beginning to Swing for Owners of Life Sciences Pate

The Patent Trial and Appeal Board is an important forum for determining a US patent’s validity. Since 2012, when inter partes review of US patents began, the PTAB’s cancellation rate for challenged patents has varied dramatically.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk




Editor's picks

Boston Scientific expands dispute with J&J unit over cardiac-access technology
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026

Editor's picks

MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026
Pharma
Behind the case: How Novartis defended its blockbuster Entresto in the UK
22 September 2026
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

More features

Novo’s semaglutide protection weakens after European ruling
UK to clamp down on non-compete clauses and long notice periods
Boston Scientific expands dispute with J&J unit over cardiac-access technology
Brazilian firm appoints patent strategist to lead department
AIPPI World Congress: ‘Diversity need not be an obstacle to unity’
Novartis pursues Apotex over copies of $2bn skin cancer drug franchise
MSD’s Keytruda hit by eight-country ban across Europe
Foley Hoag adds two partners in Denver expansion

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin